Drugs / FXB0871
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07558200 | May 2026 → Apr 2030 expected | hepatocellular carcinoma, non-small cell lung carcinoma | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma and Teva's Co-Developed Innovative Anti-Tumor Immunotherapy Drug FXB0871 Approved for Phase 1 Clinical Trial in China fosunpharma.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-29 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Announces First Participant Dosed in China Phase 1 Trial of FXB0871, an Innovative Immuno-oncology therapy fosunpharma.com ↗ |
| 2026-03-31 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma and Teva's Co-Developed Innovative Anti-Tumor Immunotherapy Drug FXB0871 Approved for Phase 1 Clinical Trial in China fosunpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXB0871 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07558200 ↗ |
| Route | Intravenous | “FXB0871 is administered by intravenous infusion” NCT07558200 ↗ |